RA0283

antibody from Oursmab

Targeting: HAVCR2 CD366, FLJ14428, Tim-3, TIM3, TIMD3

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0283

Provider

Oursmab

Product name

Surzebiclimab (Biosimilar Reference Antibody) (HAVCR2)

Antibody type

Monoclonal

Description

Surzebiclimab (BGB-A425) is a humanized IgG1 variant monoclonal antibody targeting T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), an immune checkpoint receptor. It binds to TIM-3 on T cells, NK cells, and myeloid cells to block its interaction with ligands (e.g., galectin-9, phosphatidylserine), thereby reversing immune exhaustion and enhancing anti-tumor activity. It is being developed for cancer immunotherapy, often in combination with anti-PD-1 antibodies, in advanced solid tumors and hematologic malignancies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.